| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/21/2001 | EP1083932A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine |
| 03/21/2001 | EP1083931A1 Stabilization of compositions containing ace inhibitors using magnesium oxide |
| 03/21/2001 | EP1083921A1 Novel leukotriene receptor antagonists and their uses |
| 03/21/2001 | EP1083920A1 Novel antibacterial compounds |
| 03/21/2001 | EP1083919A1 Novel antiviral compounds |
| 03/21/2001 | EP1083918A1 Novel therapeutic agents that modulate 5-ht receptors |
| 03/21/2001 | EP1083917A1 Novel analgesic agents |
| 03/21/2001 | EP1083914A1 Treatment of arthritis and other similar conditions |
| 03/21/2001 | EP1083894A1 MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE |
| 03/21/2001 | EP1083893A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the d 1? receptors |
| 03/21/2001 | EP1083892A1 Topical application of muscarinic analgesic drugs such as neostigmine |
| 03/21/2001 | EP1083888A1 MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS |
| 03/21/2001 | EP1083885A1 Delavirdine tablet formulation |
| 03/21/2001 | EP1083884A1 Stabilised polyvinylpyrrolidone formulation |
| 03/21/2001 | EP1083883A1 Stabilizers for lyophilized vaccines |
| 03/21/2001 | EP1083882A1 A hepatocyte targeting polyethylene glyco-grafted poly-l-lysine polymeric gene carrier |
| 03/21/2001 | EP1083881A2 Liposome composition and method for administering a quinolone |
| 03/21/2001 | EP1083880A1 Stable gel mixture in the form of a mixture of oleogel and aqueous gel |
| 03/21/2001 | EP1083879A1 Methods and devices for providing prolonged drug therapy |
| 03/21/2001 | EP1083861A1 Hydrous cosmetic or pharmaceutical sticks |
| 03/21/2001 | EP0717616B1 Process for conditioning substances |
| 03/21/2001 | EP0714402B9 Polymer modification |
| 03/21/2001 | CN1288388A Stabilization of lipid DNA formulations during nebulization |
| 03/21/2001 | CN1288387A Sustained release compositions, process for producing the same and utilization thereof |
| 03/21/2001 | CN1288386A Disintegrating agent |
| 03/21/2001 | CN1288385A Pharmaceutical formulations and processes for their prepn. |
| 03/21/2001 | CN1288380A Utilization of powder prepns. contg. hydroxypyridones treating LEG ulcer and decubitus ulcers |
| 03/21/2001 | CN1288376A Transdermal therapeutic system (TTS) contg. oxybutynin |
| 03/21/2001 | CN1288375A TTS contg. an antioxidant |
| 03/21/2001 | CN1288373A Prepn. of a lipid blend and a phospholipid suspension contg. the lipid blend, and contrast agents based on these |
| 03/21/2001 | CN1287830A Forming medicine pills in water contg. active compound melt material |
| 03/21/2001 | CN1063322C Aqueous liquid composition for eye external use as eyedrops |
| 03/21/2001 | CN1063321C Medicaments aerosol prepn. and preparing method therefor and releasing apparatus therefor |
| 03/21/2001 | CA2319967A1 Compositions containing proanthocyanidin and a vitamin b6 derivative or a salt thereof |
| 03/20/2001 | US6204296 Patient oxygenation using stabilized fluorocarbon emulsions |
| 03/20/2001 | US6204256 Acylated cyclodextrin derivatives |
| 03/20/2001 | US6204255 Molar ratio of sodium valproate to cyclodextrin within the range of from 1:0.01 to 1:0.09. |
| 03/20/2001 | US6204248 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 03/20/2001 | US6204247 Reacting a leptin with 0.5-5 fold molar excess of edta dianhydride to to form a monomer or dimer |
| 03/20/2001 | US6204054 Transcytosis vehicles and enchancers for drug delivery |
| 03/20/2001 | US6204036 Stable, freeze dried mixture; parenteral administering |
| 03/20/2001 | US6203814 Surface treatment of fullerene carbon; oxidation |
| 03/20/2001 | US6203794 Botulinum or tetanus toxin conjugated to drug; treating neurvous system and muscular disorders |
| 03/20/2001 | US6203789 Treating erythrocytes with s-nitroso-cysteine, homocysteine, or cysteinylglycine to reduce blood pressure |
| 03/20/2001 | US6203785 Poly(diallylamine)-based bile acid sequestrants |
| 03/20/2001 | CA2089003C Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories |
| 03/16/2001 | CA2310790A1 Cyclodextrin flavor delivery systems |
| 03/15/2001 | WO2001018181A2 Enzyme inhibitors |
| 03/15/2001 | WO2001018080A1 Uniform molecular weight polymers |
| 03/15/2001 | WO2001018077A1 Microbicidal additives |
| 03/15/2001 | WO2001018055A1 Flint analog compounds and formulations thereof |
| 03/15/2001 | WO2001018006A1 Inhibitors of prenyl-protein transferase |
| 03/15/2001 | WO2001017614A2 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 03/15/2001 | WO2001017568A2 Bioconjugation in vivo to pulmonary or blood components |
| 03/15/2001 | WO2001017567A2 Improved container composition for diagnostic agents |
| 03/15/2001 | WO2001017566A2 L-selectin contrast agents |
| 03/15/2001 | WO2001017565A2 Polyoxyalkylenes conjugates as enzyme inhibitors |
| 03/15/2001 | WO2001017564A2 Enzyme inhibitors |
| 03/15/2001 | WO2001017563A2 Integrin-mediated drug targeting |
| 03/15/2001 | WO2001017556A1 Vaccine preparations for mucosal administration |
| 03/15/2001 | WO2001017551A2 Combined vaccine compositions |
| 03/15/2001 | WO2001017549A1 Stably storable oxygen transfusion |
| 03/15/2001 | WO2001017546A1 Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| 03/15/2001 | WO2001017542A1 Protein solution preparation and method of stabilizing the same |
| 03/15/2001 | WO2001017541A1 Composition for extending post meal satiety |
| 03/15/2001 | WO2001017527A1 Preventive and therapeutic agents for eye diseases |
| 03/15/2001 | WO2001017524A1 Methods for treating cell proliferative disorders including cancer |
| 03/15/2001 | WO2001017515A1 Degradable polymers |
| 03/15/2001 | WO2001017511A1 Method of intracellular sustained-release of drug and preparations |
| 03/15/2001 | WO2001017508A1 Cationic liposome delivery of taxanes to angiogenic blood vessels |
| 03/15/2001 | WO2001017506A1 Proteinic drug delivery system using membrane mimetics |
| 03/15/2001 | WO2001017505A1 Medicinal compositions for oral use |
| 03/15/2001 | WO2001017504A1 Veterinary formulation for administration of a water-insoluble drug to a target animal through a water distribution system |
| 03/15/2001 | WO2001017501A1 Enzyme inhibitors |
| 03/15/2001 | WO2001017472A1 Using quaternary ammonium salts for transdermal drug delivery |
| 03/15/2001 | WO2001017377A1 Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said |
| 03/15/2001 | WO2001017369A1 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars' |
| 03/15/2001 | WO2001000240A3 Antitumor compound |
| 03/15/2001 | WO2000078353A3 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| 03/15/2001 | WO2000071125A3 Pharmaceutical preparation containing the active substance diamorphine and its utilization in a method for treating opiate addiction |
| 03/15/2001 | WO2000066174A3 Compounds |
| 03/15/2001 | WO2000064468A3 Therapeutic compositions and methods for enhancing angiogenesis |
| 03/15/2001 | WO2000064418A3 Transdermal therapeutic system with neutralized acrylic adhesive patch |
| 03/15/2001 | WO2000062814A3 Intracellular pharmaceutical targeting |
| 03/15/2001 | WO2000057854A3 Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances |
| 03/15/2001 | US20010000029 A stable gel composition comprising a polyacrylic acid compound, a polyvalent metal component and 75-95 % weight of water user for a covering or laminated sheet to cool bodies to induce sleep |
| 03/15/2001 | DE19943501A1 Unterwassergranulation wirkstoffhaltiger Schmelzen Underwater granulation medicated melting |
| 03/15/2001 | DE19943491A1 Verbesserte Komprimate Improved compressed |
| 03/15/2001 | DE19940944A1 Retardierte, orale, pharmazeutische Darreichungsformen Prolonged-release oral pharmaceutical dosage forms |
| 03/15/2001 | DE10044420A1 Tissue-compatible composite for prolonged, controlled drug release, comprising drug-impregnated composite obtained by bonding two ceramic bodies, preferably used as bone substitute |
| 03/15/2001 | DE10013849A1 L-Selectin-Kontrastmittel L-selectin contrast agent |
| 03/15/2001 | CA2384679A1 Using quaternary ammonium salts for transdermal drug delivery |
| 03/15/2001 | CA2384531A1 Antimicrobial additives |
| 03/15/2001 | CA2384151A1 Inhibitors of prenyl-protein transferase |
| 03/15/2001 | CA2383981A1 Integrin-mediated drug targeting |
| 03/15/2001 | CA2383971A1 Prophylactic and therapeutic medicaments for ophthalmic diseases |
| 03/15/2001 | CA2383798A1 Pulmonary delivery for bioconjugation |
| 03/15/2001 | CA2383794A1 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 03/15/2001 | CA2383720A1 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of "fast sugars" |
| 03/15/2001 | CA2383523A1 Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said |